Navigation Links
Versartis presents positive preclinical data on 2 product candidates at ENDO 09
Date:6/10/2009

Washington, DC June 10, 2009 Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic diseases, today presented data for its long-acting product candidates, VRS-317 (hGH-rPEG) for treatment of growth hormone deficiency and for VRS-826 (IL-1ra-rPEG) for treatment of type 1 and type 2 diabetes, at the Endocrine Society's Annual Meeting in Washington, DC.

Versartis, through a unique licensing agreement with Amunix, Inc., uses the Amunix proprietary recombinant PEGylation (rPEG) technology to extend the half-life of established biologics. The preclinical Versartis compounds have the potential for significantly less frequent dosing and fewer side effects than those products currently on the market or in development.

"New half-life extension data presented today for the first time confirmed our expectation that dosing can be extended from weekly to monthly for our product candidates," said Jeffrey L. Cleland, Ph.D., Founder and Chief Executive Officer of Versartis. "Our preclinical data presented today show that VRS-317 demonstrated in vivo potency equal to daily hGH, and sustained plasma levels and pharmacodynamic responses in monkeys without toxicity. Potential benefits of VRS-317 include its stability at room temperature in a liquid formulation and the ability to dose monthly with a small gauge needle, thus increasing patient safety and convenience. VRS-317 may become 'best in class' hGH therapy when our preclinical studies are confirmed in human clinical trials."

"Treatment of auto-inflammation in diabetes with IL-1ra has been demonstrated to increase beta-cell responsiveness in human clinical trials," Dr. Cleland continued. "Our new approach with VRS-826 will provide a less frequently administered treatment that should have comparable safety to IL-1ra, which binds both IL-1b and IL-1a. The results from preclinical studies of VRS-317 and VRS-826 are being presented in poster ses
'/>"/>

Contact: Debra Bannister
media@versartis.com
530-676-8001
Versartis, Inc.
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
2. Biolex presents Locteron US Phase 2a hepatitis C data at EASL
3. GSA special paper presents new studies of Western US earth motion
4. AIUM Presents 2009 Joseph H. Holmes Pioneer Awards
5. AIUM presents 2009 Memorial Hall of Fame awards
6. AIUM presents 2009 Distinguished Sonographer award
7. AIUM presents 2009 William J. Fry Memorial Lecture award
8. Stevens Center for Science Writings presents: Ravens at the Feast, with Bernd Heinrich, April 1
9. Understanding soil carbon sequestration: New book presents key concepts
10. World Congress on Osteoporosis 2010 presents outstanding scientific program
11. New manual presents robust, state-of-the-art proteomics methods for teaching and research

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...a Romeo Casabona is Director of the Interuniversit...usto University and the University of the Basque C...rists but also has other experts such as researche...d even specialists in ethics. , The Interunivers...the Universities of Deusto and the Basque Country ...
(Date:11/22/2009)... -- Children exposed prenatally to tobacco smoke a...gh risk for ADHD, according to research done at Ci...he study estimates that up to 35 percent of ADHD c...d be reduced by eliminating both of these environm...00,000 children , "Tobacco and lead exposure ea...
(Date:11/22/2009)...e, MA November 23, 2009 Agios Pharmaceuticals to..., for the first time, that the mutated IDH1 gene h...r-causing gene, or oncogene. This breakthrough dis...s a metabolite, 2-hydroxyglutarate (2HG), which ma...ssion of gliomas, the most common type of brain ca...
Breaking Biology News(10 mins):Research and legislation should go hand in hand, as much as possible 2Exposure to lead, tobacco smoke raises risk of ADHD 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 2Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 3Cancer metabolism discovery uncovers new role of IDH1 gene mutation in brain cancer 4From Jack the Ripper to great white sharks 8940 1Transplant drug stimulates immune memory 49553 1Transplant drug stimulates immune memory 49553 2Fate in fly sensory organ precursor cells could explain human immune disorder 8938 1Fate in fly sensory organ precursor cells could explain human immune disorder 8938 2Fate in fly sensory organ precursor cells could explain human immune disorder 8938 3
...ashington University in St. Louis is making molecu...thousands of minuscule electrodes on a tiny comput...ules that bind to receptor sites. Kevin Moeller, P... in Arts & Sciences, is doing this so that the... biological behavior of up to 12,000 molecules at ...
...ve demonstrated for the first time that malfunctio...renia and depression does indeed cause symptoms of... offer a possible animal model for developing trea...y said their findings support the theory that the ...teven Clapcote, David Porteous, John Roder, and co...
...e syndrome (CFS) has been associated with altered ...duced electroencephalograph (EEG) activity and imp...May 1st issue of the journal SLEEP finds that CFS ...ty (SWA) response to sleep challenge, suggesting a...tic response. , The study, authored by Roseanna Ar...
Other Biology News:Technique monitors thousands of molecules simultaneously 2Technique monitors thousands of molecules simultaneously 3Technique monitors thousands of molecules simultaneously 4Gene malfunctions cause schizophrenia, depression symptoms in mice 2
(Date:11/20/2009)... , ROCKVILLE, Md., Nov. 20 /PRNewswire-FirstCa...ced that it has priced an underwritten public offe...price to the public of $3.30 per share. The appro...ing the underwriting discounts and commissions, wi...ials of our VLP-based vaccines, internal research ...
(Date:11/20/2009)... , SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -...TIC) announced today that the Ninth Circuit Court ...d ruled that CTI should be allowed to pursue all o...ase back to the District Court for trial. CTI fil...r third-party reimbursement consultant for CTI,s p...
(Date:11/20/2009)... METTLER TOLEDO recently announ...e webinar, “The Role of Process Analytical T...eering” on December 1, 2009. , ...e The Role of Process Analytical Technology (PAT)... on December 1, Process Analytical Technology (PAT...
(Date:11/19/2009)..., COPENHAGEN, Nov. 19 Danish Pri...n cellulosic ethanol plant in Kalundborg, Denmark,... the world,s first and largest 2nd generation etha...erase enzymes are used in the plant,s innovative p...ivision of Danisco, was the first to market with c...
Breaking Biology Technology:Novavax Prices Public Offering of Common Stock 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2
...f., Oct. 18 Nile Therapeutics,Inc. (OTC Bulletin ...ed on,developing therapies for cardiovascular dise... appointed on October 16, 2007 to serve on its boa...ted pharmaceutical industry,leader with over 30 ye...esources, manufacturing and quality assurance. "W...
...tional HapMap Consortium today published analyses ...ation, which contains three times more markers tha...ers in the journal Nature, the consortium describe...er to detect genetic variants involved in common d...riation and learn how environmental factors, such ...
...CISCO, Calif., Oct. 17 Monogram,Biosciences, Inc....onference,call on Wednesday, October 24, 2007 at 4...007 financial results. The call will be hosted by .... To participate in the live teleconference, plea...national callers, fifteen minutes before the,confe...
Other Biology Technology:Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 2Nile Therapeutics Appoints Pedro Granadillo to Board of Directors 3Consortium publishes Phase II map of human genetic variation 2Consortium publishes Phase II map of human genetic variation 3Consortium publishes Phase II map of human genetic variation 4Consortium publishes Phase II map of human genetic variation 5Consortium publishes Phase II map of human genetic variation 6Monogram Biosciences Announces Third Quarter 2007 Financial Results Conference Call 2
...e iCycler thermal cycler with 384-well reaction mo...applications. It is equipped with an interchangeab...les) and features algorithm temperature monitoring... small sample volumes. It includes the iCycler bas...
RAT LD NORMAL TISSUE ARRAY from BioGenex
...e Multiple Species Tissue Array (MSTA) slides were...different cells and tissues from multiple species....ounted on each MSTA slide which can then be treate... immunohistochemistry, or in situ hybridization....
...ybean-Casein Digest Medium (TSB), USP is a highly ...or general laboratory use. Due to the inclusion of...pport growth of many fastidious organisms without ... United States Pharmacopeia standards for use in M...
Biology Products: